journal article·2024-02Open access

Nanosponges as an Emerging Platform for Cancer Treatment and Diagnosis

B. H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Mohammad Ali Abdullah Almoyad, Shadma Wahab, Waleed H. Almalki, Prashant Kesharwani

Advanced Functional Materials· Volume 34· Issue 7

Abstract

Abstract Nanosponges are unique sponge‐like carrier systems with numerous cavities and a mesh‐like network throughout their surface. They are categorized into three types based on the material of construction, i.e., polymer‐, inorganic‐, and bio‐derived material‐based nanosponges. Unlike conventional nanoparticles, nanosponges bear countless interconnected voids and mesh‐like network that enables maximum drug, imaging probe, or photosensitizer loading via absorption, encapsulation, conjugation, or complexion. The voids can be further sealed using suitable lipids or polymers to avoid leakage of drugs at the non‐target site, protect therapeutics from biological conditions, and control the release of therapeutics for a prolonged period. Recently, nanosponges have grasped the attention of researchers in the area of cancer by overcoming the drawbacks associated with the conventional delivery of immunotherapeutic, targeted therapeutic, and chemotherapeutic agents. Interestingly, several reports have also witnessed their potential in cancer theranostics. Owing to this supremacy, nanosponges could be an apt platform for cancer therapy and diagnosis. The current review discusses the general aspects, types, and preparation methods of nanosponges. In addition, the ambit of nanosponges in treating different types of cancer is meticulously discussed, along with detailed descriptions of their corresponding patents. Furthermore, the role of nanosponges in phototherapy and cancer theranostics are selectively canvassed.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics Yenepoya Pharmacy College & Research Centre Yenepoya (Deemed to be University) Mangalore Karnataka 575018 India

Department of Basic Medical Sciences College of Applied Medical Sciences King Khalid University Khamis Mushyt, PO Box 4536 Abha 61412 Saudi Arabia

Department of Pharmacognosy College of Pharmacy King Khalid University Abha 62529 Saudi Arabia

Department of Pharmacology and Toxicology Faculty of Pharmacy Umm Al‐Qura University Makkah 24381 Saudi Arabia

Department of Pharmaceutics School of Pharmaceutical Education and Research Jamia Hamdard New Delhi 110062 India

Funding

King Khalid University

References (100+)

Show source-provided references
1. 10.1016/S0140-6736(22)01430-110.1016/S0140-6736(22)01430-1 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. 10.1136/bmj.c267210.1136/bmj.c2672 ↗
4. Cancer Facts for Men (n.d.).https://www.cancer.org/healthy/cancer‐facts/cancer‐facts‐for‐men.html(accessed: March 2023).
5. Cancer Facts for Women | Most Common Cancers in Women (n.d.).https://www.cancer.org/healthy/cancer‐facts/cancer‐facts‐for‐women.html(accessed: March 2023).
6. Cancer (n.d.).https://www.who.int/news‐room/fact‐sheets/detail/cancer(accessed: March 2023).
7. 10.1136/esmoopen-2017-00028510.1136/esmoopen-2017-000285 ↗
8. 10.1016/S0140-6736(98)90327-010.1016/S0140-6736(98)90327-0 ↗
9. 10.1016/j.envres.2023.11689410.1016/j.envres.2023.116894 ↗
10. Recurrent Cancer – NCI (n.d.).https://www.cancer.gov/types/recurrent‐cancer(accessed: March 2023).
11. Treatment of Recurrent Breast Cancer (n.d.).https://www.cancer.org/cancer/breast‐cancer/treatment/treatment‐of‐breast‐cancer‐by‐stage/treatment‐of‐recurrent‐breast‐cancer.html(accessed: March 2023).
12. Ghate S. R. · Am. Health Drug Benefits · 2018 · 11 · 334
13. 10.21037/atm.2018.03.2810.21037/atm.2018.03.28 ↗
14. 10.3389/fphar.2018.0024510.3389/fphar.2018.00245 ↗
15. Altun İ. · Iran J. Public Health · 2018 · 47 · 1218
16. Zeng L. · Mol. Cancer · 2023 · 22 · 110.1186/s12943-022-01695-6 ↗
17. 10.1016/j.jddst.2022.10330510.1016/j.jddst.2022.103305 ↗
18. 10.3390/pharmaceutics1408157610.3390/pharmaceutics14081576 ↗
19. 10.1080/09205063.2022.206540810.1080/09205063.2022.2065408 ↗
20. 10.1186/s43094-020-00150-x10.1186/s43094-020-00150-x ↗
21. 10.1016/j.ijpharm.2023.12327610.1016/j.ijpharm.2023.123276 ↗
22. 10.1016/j.eurpolymj.2023.11211110.1016/j.eurpolymj.2023.112111 ↗
23. K.Paul B. H. J.Gowda F.Damiri Y. R.Hemalatha R. S.Chandan M.Berrada inPolymer Nanocomposites CRC Press FL USA2023.
24. 10.7150/thno.6962810.7150/thno.69628 ↗
25. 10.1016/j.heliyon.2022.e0940310.1016/j.heliyon.2022.e09403 ↗
26. 10.1016/j.pmatsci.2019.03.00310.1016/j.pmatsci.2019.03.003 ↗
27. 10.1016/j.drudis.2014.12.01210.1016/j.drudis.2014.12.012 ↗
28. 10.1016/j.jconrel.2021.02.01610.1016/j.jconrel.2021.02.016 ↗
29. 10.1186/s12935-021-02025-410.1186/s12935-021-02025-4 ↗
30. 10.1007/12_2021_10110.1007/12_2021_101 ↗
31. 10.1016/j.ijbiomac.2022.07.06810.1016/j.ijbiomac.2022.07.068 ↗
32. He L. · Biomed. Res. Int. · 2020 · 2020 · 7259
33. 10.1016/j.matpr.2022.06.10110.1016/j.matpr.2022.06.101 ↗
34. 10.2174/156720181866621060916130110.2174/1567201818666210609161301 ↗
35. Current Nanotechnology Treatments – NCI (n.d.).https://www.cancer.gov/nano/cancer‐nanotechnology/current‐treatments(accessed: March 2023).
36. 10.1517/17425247.2014.91172910.1517/17425247.2014.911729 ↗
37. 10.18433/J3K30810.18433/J3K308 ↗
38. 10.1007/s10856-022-06652-910.1007/s10856-022-06652-9 ↗
39. B. H. J.Gowda K.Paul M. G.Ahmed inAn Introduction to Drug Carriers Nova Science Publishers NY USA2021.
40. 10.3390/polym1506154310.3390/polym15061543 ↗
41. 10.3390/ijms2406532210.3390/ijms24065322 ↗
42. C.Molinar S.Navarro‐Orcajada I. A.Ansari I.Conesa G.Hoti Y. K.Monfared A.Matencio A.Scomparin J. M.López‐Nicolás R.Cavalli F.Trotta inTargeted Cancer Therapy in Biomedical Engineering(Eds.:R.Malviya S.Sundram) Springer Berlin Germany2023.
43. 10.1016/j.ijpharm.2023.12288310.1016/j.ijpharm.2023.122883 ↗
44. 10.1016/j.jddst.2022.10406510.1016/j.jddst.2022.104065 ↗
45. 10.3390/nano1214244010.3390/nano12142440 ↗
46. 10.2174/138945011666615100110544910.2174/1389450116666151001105449 ↗
47. R. A. M.Osmani P. K.Kulkarni V.Gowda U.Hani V. K.Gupta M.Prerana C.Saha inApplications of Nanocomposite Materials in Drug Delivery Woodhead Publishing Cambridge2018.
48. 10.1016/j.jddst.2021.10293110.1016/j.jddst.2021.102931 ↗
49. 10.1016/j.carbpol.2017.05.08610.1016/j.carbpol.2017.05.086 ↗
50. 10.1007/s11356-021-15187-510.1007/s11356-021-15187-5 ↗
51. 10.3390/polym1323411010.3390/polym13234110 ↗
52. 10.3390/app1023846310.3390/app10238463 ↗
53. 10.1016/S2222-1808(14)60667-810.1016/S2222-1808(14)60667-8 ↗
54. 10.1103/PhysRevB.49.1428210.1103/PhysRevB.49.14282 ↗
55. 10.1021/ma951673i10.1021/ma951673i ↗
56. 10.1016/S0015-1882(00)80050-610.1016/S0015-1882(00)80050-6 ↗
57. 10.1089/oli.1.1999.9.30110.1089/oli.1.1999.9.301 ↗
58. 10.1007/s10847-006-9085-210.1007/s10847-006-9085-2 ↗
59. 10.3109/1071754100377723310.3109/10717541003777233 ↗
60. 10.1016/j.ijpharm.2010.09.02510.1016/j.ijpharm.2010.09.025 ↗
61. 10.3109/1083745100373928910.3109/10837451003739289 ↗
62. 10.2174/15672011179447993410.2174/156720111794479934 ↗
63. 10.1166/jnn.2013.777010.1166/jnn.2013.7770 ↗
64. 10.1038/nnano.2013.5410.1038/nnano.2013.54 ↗
65. 10.1039/c4py00207e10.1039/c4py00207e ↗
66. 10.1021/acsnano.6b0441410.1021/acsnano.6b04414 ↗
67. 10.1016/j.nano.2017.07.00410.1016/j.nano.2017.07.004 ↗
68. 10.1038/s41598-016-0028-x10.1038/s41598-016-0028-x ↗
69. 10.1038/s41598-017-00037-710.1038/s41598-017-00037-7 ↗
70. 10.1021/acs.molpharmaceut.8b0050810.1021/acs.molpharmaceut.8b00508 ↗
71. 10.1007/s12668-022-01000-110.1007/s12668-022-01000-1 ↗
72. 10.1016/j.jddst.2020.10164310.1016/j.jddst.2020.101643 ↗
73. 10.1016/j.msec.2017.06.00410.1016/j.msec.2017.06.004 ↗
74. 10.3390/molecules2516373110.3390/molecules25163731 ↗
75. 10.3390/nano1007140310.3390/nano10071403 ↗
76. 10.3389/fphar.2021.60162610.3389/fphar.2021.601626 ↗
77. 10.1016/j.mtchem.2022.10131910.1016/j.mtchem.2022.101319 ↗
78. 10.1016/j.jddst.2021.10268410.1016/j.jddst.2021.102684 ↗
79. 10.1016/j.ijpharm.2019.05.01510.1016/j.ijpharm.2019.05.015 ↗
80. 10.1039/C5CC01558H10.1039/C5CC01558H ↗
81. 10.1016/j.matchemphys.2008.04.01610.1016/j.matchemphys.2008.04.016 ↗
82. 10.1039/c0gc00648c10.1039/c0gc00648c ↗
83. 10.1039/C5TA00382B10.1039/C5TA00382B ↗
84. 10.3390/nano1205075410.3390/nano12050754 ↗
85. 10.3390/w1403050510.3390/w14030505 ↗
86. 10.3390/ijms2111407910.3390/ijms21114079 ↗
87. 10.1016/j.jcis.2019.08.04610.1016/j.jcis.2019.08.046 ↗
88. 10.1002/adma.20160248610.1002/adma.201602486 ↗
89. Chhabria V. · Nanomedicine · 2016 · 11 · 2797
90. 10.1021/acsami.9b1828210.1021/acsami.9b18282 ↗
91. 10.1161/CIRCRESAHA.122.32103410.1161/CIRCRESAHA.122.321034 ↗
92. 10.3109/03639045.2015.104490310.3109/03639045.2015.1044903 ↗
93. 10.1016/j.jddst.2019.04.02510.1016/j.jddst.2019.04.025 ↗
94. 10.3762/bjoc.16.12710.3762/bjoc.16.127 ↗
95. 10.1016/j.ultsonch.2016.06.01810.1016/j.ultsonch.2016.06.018 ↗
96. 10.1007/s10934-014-9851-210.1007/s10934-014-9851-2 ↗
97. 10.1016/j.matpr.2016.11.05510.1016/j.matpr.2016.11.055 ↗
98. 10.1007/s12013-014-0459-610.1007/s12013-014-0459-6 ↗
99. 10.1016/j.ctarc.2021.10046910.1016/j.ctarc.2021.100469 ↗
100. 10.5306/wjco.v5.i3.41210.5306/wjco.v5.i3.412 ↗